The globalvirtual clinical trials marketsize is expected to reach USD 12.9 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.7% from 2022 to 2030. The COVID-19 pandemic has significantly impacted the market. The growing need for patient diversity clubbed with enhanced data collection inclinical trialsis boosting the market growth.
There has been a rise in the R&D of new drugs andvaccinesthat has increased the volume and complexity of clinical trials. Virtual clinical trials eliminate challenges posed by traditional clinical trials for example delays in patient recruitment and time-consuming procedures. Also, studies have revealed that around 75.0% of people favored a mobile trial over traditional ones and 80.0% of patients are more likely to participate in a clinical trial that uses mobile technology.
The market is recovering at a significant pace after the pandemic as it offers various benefits to patients as well as sponsors. During the pandemic, traveling was potentially dangerous. It can be expensive, even incurring lost wages or requiring that childcare/eldercare be hired. These drawbacks limit initial interest and provide a simple solution for virtual clinical trials. Virtual clinical trials offer various benefits such as effective data collection, analysis, and monitoring large amounts of data in real-time.
Virtual trials make use of monitoring devices, software apps, online social engagement platforms to conduct every step of the clinical trial process including patient recruitment, counseling, measuring clinical endpoints, informed consent, and adverse reactions. Telehealth, home care, and remote patient monitoring has been gaining momentum as a healthcare offering, and the COVID-19 is adding more horsepower to this initiative.
Request a free sample copy or view report summary:Virtual Clinical Trials Market Report
The oncology segment held 25.2% of the revenue share in 2021. The increasing adoption of virtual trials especially in oncology clinical research for the diverse populations is responsible for the growth of the segment
The interventional design segment accounted for the largest revenue share of 46.7% in 2021
North America held 49.2% of the revenue share in 2021. Favorable government initiatives and the presence of large numbers of players in the U.S. offerings advanced services are responsible for market growth
In Asia Pacific, the market is expected to witness the fastest CAGR of 6.8% over the forecast period owing to the increasing patient pool and cost-efficient services
绿草nd View Research has segmented the global virtual clinical trials market based on study design, indication, phase and region:
VirtualClinical TrialsStudy Design Outlook (Revenue, USD Million, 2017 - 2030)
Interventional
Observational
Expanded Access
VirtualClinical TrialsIndicationOutlook (Revenue, USD Million, 2017 - 2030)
CNS
Autoimmune/Inflammation
Cardiovascular Disease
Metabolic/Endocrinology
Infectious Disease
Oncology
Genitourinary
Ophthalmology
Others
VirtualClinical TrialsPhaseOutlook (Revenue, USD Million, 2017 - 2030)
Phase I
Phase II
Phase III
Phase IV
VirtualClinical TrialsRegional Outlook (Revenue, USD Million, 2017 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Asia Pacific
India
Japan
China
Australia
South Korea
Latin America
Brazil
Mexico
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
List of Key Players ofVirtual Clinical Trials Market
ICON, plc
Parexel International Corporation
IQVIA
Covance
PRA Health Sciences
LEO Innovation Lab
Medidata
Oracle
CRF Health
Clinical Ink
Medable, Inc.
Signant Health
Clinical Ink
Halo Health Systems
Croprime
"The quality of research they have done for us has been excellent..."